Company intelligence / Profile preview
Huons Biopharma
Seongnam-si, Gyeonggi-do, South Koreahuonsbiopharma.com ↗
- Ownership
- Private
- Employees
- ~900
- Development stage
- Other
01
Overview
Huons Biopharma has commercialized Botulinum Toxin Type-A and maintains a diverse pipeline with late-stage clinical programs targeting upper limb spasticity and dry eye syndromes. The company continues to expand its aesthetics portfolio through strategic partnerships[5][6][9].
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Botulinum toxinSmall moleculeSynthetic peptideBiological product
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
VERNI Aesthetics – strategic investment and collaboration on MRC101 aesthetics program[6]
Beyond the preview
Go deeper on Huons Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huons Biopharma.